Published Paper Details:

Artificial intelligence is changing the landscape of the pharmaceutical industry simply because it analyzes humongous data, which hastens the process of clinical trials and drug development. For the exact purpose to instance, with machine learning, natural language processing, and predictive analytics, the process of finding drug candidates can be fine-tuned along with predictions on how a patient is going to react to a treatment and hence developing specific therapy plans. This strategy reduces both the time and expenses associated with introducing new drugs to the market. Furthermore, AI technologies evaluate chemical and biological information during the drug discovery phase to predict safety and effectiveness, thus speeding up screening processes. AI-driven solutions pinpoint patient populations and track real-time data to refine trial designs and ensure regulatory compliance. The implementation of AI in the pharmaceutical industry necessitates collaborative efforts aimed at the future, engaging technologists, regulatory bodies, and academic institutions to advance pharmaceuticals. Highlighting the significance of data integrity, privacy, and ethics, and generating real-world evidence is vital for enhancing patient safety and enabling proactive medication assessments. This application will encourage adaptable, patient-focused healthcare, hasten the availability of medications, and improve treatment options to achieve optimal results. The goal of integrating these systems is to drive progress in treatment alternatives.